Jennifer Buell is President and Chief Executive Officer of MiNK Therapeutics, a clinical‑stage biopharmaceutical company developing off‑the‑shelf invariant natural killer T (iNKT) cell therapies for cancer and immune‑mediated diseases. She has served as CEO of MiNK since 2021 and also chairs the Executive Council of Agenus, where she serves in the Board of Directors, bringing more than 27 years of biopharmaceutical leadership experience. During her tenure in Agenus, her team transformed the company from a single‑product organization into a global, integrated biotech business with a robust immuno‑oncology portfolio through expanded strategic partnerships and operational capabilities.
Under Buell’s leadership at MiNK Therapeutics, the company has advanced multiple iNKT cell programs into clinical development, including Phase 2 studies in solid tumors and expanded indications, and has secured significant financing and federal grants to support allogeneic cell therapy research. She has overseen presentations of clinical data at major scientific forums and led strategic initiatives to broaden MiNK’s pipeline across oncology and inflammatory diseases. Buell held senior R&D and operational leadership roles at Bristol‑Myers Squibb and the Harvard Clinical Research Institute earlier in her career, grounding her executive impact in deep scientific and clinical development expertise.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
